Soleno Therapeutics (FRA:6XC) Total Stockholders Equity : €238.49 Mil (As of Sep. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Soleno Therapeutics Total Stockholders Equity?

Soleno Therapeutics's Total Stockholders Equity for the quarter that ended in Sep. 2024 was €238.49 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Soleno Therapeutics's Book Value per Share for the quarter that ended in Sep. 2024 was €5.81. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Soleno Therapeutics's Debt-to-Equity for the quarter that ended in Sep. 2024 was 0.01.

Soleno Therapeutics Total Stockholders Equity Historical Data

The historical data trend for Soleno Therapeutics's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Soleno Therapeutics Total Stockholders Equity Chart

Soleno Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Stockholders Equity

Get a 7-Day Free Trial

13.45

37.44

15.75

9.77

144.43

Soleno Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Total Stockholders Equity	Get a 7-Day Free Trial															21.76	144.43	131.92	260.82	238.49

Soleno Therapeutics (FRA:6XC) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Soleno Therapeutics's Book Value per Share for the quarter that ended in Sep. 2024 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(238.494	-	0)	/	41.0412
	=	5.81

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Soleno Therapeutics's Debt-to-Equity for the quarter that ended in Sep. 2024 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.404	+	2.325)	/	238.494
	=	0.01

Soleno Therapeutics Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Soleno Therapeutics's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Soleno Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Soleno Therapeutics Inc (FRA:6XC) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

SLNO:USA

Address

203 Redwood Shores Parkway, Suite 500, Redwood City, CA, USA, 94065

Website

https://www.soleno.life

Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet for the treatment of Prader-Willi Syndrome. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine.

Soleno Therapeutics Headlines

No Headlines